ProperdinFE exhibited perfect diagnostic metrics (100% accuracy, specificity and sensitivity) in distinguishing active LN from other SLE, and from inactive SLE, outperforming uProperdin as well as conventional disease activity markers such as anti-dsDNA, C3 and C4. This evidence concerns the gene C4A and lobular neoplasia.